pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-103b-1 |
Genomic Coordinates | chr5: 168560904 - 168560965 |
Description | Homo sapiens miR-103b-1 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-103b-2 |
Genomic Coordinates | chr20: 3917502 - 3917563 |
Description | Homo sapiens miR-103b-2 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-103b | |||||||||||||||||||||
Sequence | 1| UCAUAGCCCUGUACAAUGCUGCU |23 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | ChIP-seq | DRVs in miRNA |
|
|||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CA12 | ||||||||||||||||||||
Synonyms | CA-XII, CAXII, HsT18816, T18816 | ||||||||||||||||||||
Description | carbonic anhydrase 12 | ||||||||||||||||||||
Transcript | NM_001218 | ||||||||||||||||||||
Other Transcripts | NM_206925 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on CA12 | |||||||||||||||||||||
3'UTR of CA12 (miRNA target sites are highlighted) |
>CA12|NM_001218|3'UTR 1 GGTCCCCGGAGCTCCCGGGCACATCCAGGAAGGACCTTGCTTTGGACCCTACACACTTCGGCTCTCTGGACACTTGCGAC 81 ACCTCAAGGTGTTCTCTGTAGCTCAATCTGCAAACATGCCAGGCCTCAGGGATCCTCTGCTGGGTGCCTCCTTGCCTTGG 161 GACCATGGCCACCCCAGAGCCATCCGATCGATGGATGGGATGCACTCTCAGACCAAGCAGCAGGAATTCAAAGCTGCTTG 241 CTGTAACTGTGTGAGATTGTGAAGTGGTCTGAATTCTGGAATCACAAACCAAGCCATGCTGGTGGGCCATTAATGGTTGG 321 AAAACACTTTCATCCGGGGCTTTGCCAGAGCGTGCTTTCAAGTGTCCTGGAAATTCTGCTGCTTCTCCAAGCTTTCAGAC 401 AAGAATGTGCACTCTCTGCTTAGGTTTTGCTTGGGAAACTCAACTTCTTTCCTCTGGAGACGGGGCATCTCCCTCTGATT 481 TCCTTCTGCTATGACAAAACCTTTAATCTGCACCTTACAACTCGGGGACAAATGGGGACAGGAAGGATCAAGTTGTAGAG 561 AGAAAAAGAAAACAAGAGATATACATTGTGATATATTAGGGACACTTTCACAGTCCTGTCCTCTGGATCACAGACACTGC 641 ACAGACCTTAGGGAATGGCAGGTTCAAGTTCCACTTCTTGGTGGGGATGAGAAGGGAGAGAGAGCTAGAGGGACAAAGAG 721 AATGAGAAGACATGGATGATCTGGGAGAGTCTCACTTTGGAATCAGAATTGGAATCACATTCTGTTTATCAAGCCATAAT 801 GTAAGGACAGAATAATACAATATTAAGTCCAAATCCAACCTCCTGTCAGTGGAGCAGTTATGTTTTATACTCTACAGATT 881 TTACAAATAATGAGGCTGTTCCTTGAAAATGTGTTGTTGCTGTGTCCTGGAGGAGACATGAGTTCCGAGATGACCCAATC 961 TGCCTTTGAATCTGGAGGAAATAGGCAGAAACAAAATGACTGTAGAACTTATTCTCTGTAGGCCAAATTTCATTTCAGCC 1041 ACTTCTGCAGGATCCCTACTGCCAACCTGGAATGGAGACTTTTATCTACTTCTCTCTCTCTGAAGATGTCAAATCGTGGT 1121 TTAGATCAAATATATTTCAAGCTATAAAAGCAGGAGGTTATCTGTGCAGGGGGCTGGCATCATGTATTTAGGGGCAAGTA 1201 ATAATGGAATGCTACTAAGATACTCCATATTCTTCCCCGAATCACACAGACAGTTTCTGACAGGCGCAACTCCTCCATTT 1281 TCCTCCCGCAGGTGAGAACCCTGTGGAGATGAGTCAGTGCCATGACTGAGAAGGAACCGACCCCTAGTTGAGAGCACCTT 1361 GCAGTTCCCCGAGAACTTTCTGATTCACAGTCTCATTTTGACAGCATGAAATGTCCTCTTGAAGCATAGCTTTTTAAATA 1441 TCTTTTTCCTTCTACTCCTCCCTCTGACTCTAAGAATTCTCTCTTCTGGAATCGCTTGAACCCAGGAGGCGGAGGTTGCA 1521 GTAAGCCAAGGTCATGCCACTGCACTCTAGCCTGGGTGACAGAGCGAGACTCCATCTCAAAAAAAAAAAAAAAAAAATTA 1601 TTCTGTACCATCACAACTTTTCACAACGATGGCAAGCCTTATGTCTTGGGAGCCTGTTTTGCTAGGCAAAGTTACAAGTG 1681 ACCTAATGGGAGCTCAAATGTGTGTGTGTCTCTCTGTGTGTTTGTGTGTGTGTGTGCACTCAAGACCTCTAACAGCCTCG 1761 AAGCCTGGGGTGGCATCCCGGCCTTGCCATTAGCATGCCTCATGCATCATCAGATGACAAGGACAACCCTCATGACGAAG 1841 CAACATGAATTAGGGGGCCTCTTGGCCTTGGTCCAAAATTGTCAATCAGAAATGAACATAAAGGACTCCAGAGCAGTGGG 1921 ACTGTCTGTCAAAAGACTCTGTATATCTTTTGTGGATGAGTTTTGTGAGAGAACAGAGAGACCATTGTACCTGGCACAAG 2001 GGCTGTTCATGAAAAGGGAGACTTACTGGGAGGTGCAAGACAGTGGCATTTCTCCTCTCCTCTTGCTGCTCAGCACAGCC 2081 CTGGATTGCAGCCCCGAGGCTGAGACCAGACAAAGCCCGGGAGGCAGAAAGATGCTCCAAGAACCAACACTATCAATGTC 2161 TTTGCAAATCCTCACAGGATTCCTGTGGGTCCAGCTTTGGAACTGGGAAACCTTTCTTCGGATCCGCACTCATTCCACTG 2241 ATGCCAGCTGCCCCTGAAGGATGCCAGTACTGTGGTGTGTGAGTCTCAGCAGCCGCCCACACGCTCCTAACTCTGCTGCA 2321 TGGCAGATGCCTAGGTGGAAATAGCAAAAACAAGGCCCAGGCTGGGGCCAGGGCCAGAGGGGAAGGCCCTGGATTCTCAC 2401 TCATGTGAGATCTTGAATCTCTTTCTTTGTTCTGTTTGTTTAGTTAGTATCATCTGGTAAAATAGTTAAAAAACAACAAA 2481 AAACTCTGTATCTGTTTCTAGCATGTGCTGCATTGACTCTATTAATCACATTTCAAATTCACCCTACATTCCTCTCCTCT 2561 TCACTAGCCTCTCTGAAGGTGTCCTGGCCAGCCCTGGAGAAGCACTGGTGTCTGCAGCACCCCTCAGTTCCTGTGCCTCA 2641 GCCCACAGGCCACTGTGATAATGGTCTGTTTAGCACTTCTGTATTTATTGTAAGAATGATTATAATGAAGATACACACTG 2721 TAACTACAAGAAATTATAAATGTTTTTCACATCA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545216. RNA binding protein: AGO2. Condition:miR-124 transfection
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Disease | 771.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM714644. RNA binding protein: AGO2. Condition:completeT1
"PAR-CLIP data was present in GSM714645. RNA binding protein: AGO2. Condition:completeT1
... - Kishore S; Jaskiewicz L; Burger L; Hausser et al., 2011, Nature methods. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Kishore S; Jaskiewicz L; Burger L; Hausser et al. - Nature methods, 2011
Cross-linking and immunoprecipitation (CLIP) is increasingly used to map transcriptome-wide binding sites of RNA-binding proteins. We developed a method for CLIP data analysis, and applied it to compare CLIP with photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) and to uncover how differences in cross-linking and ribonuclease digestion affect the identified sites. We found only small differences in accuracies of these methods in identifying binding sites of HuR, which binds low-complexity sequences, and Argonaute 2, which has a complex binding specificity. We found that cross-link-induced mutations led to single-nucleotide resolution for both PAR-CLIP and CLIP. Our results confirm the expectation from original CLIP publications that RNA-binding proteins do not protect their binding sites sufficiently under the denaturing conditions used during the CLIP procedure, and we show that extensive digestion with sequence-specific RNases strongly biases the recovered binding sites. This bias can be substantially reduced by milder nuclease digestion conditions.
LinkOut: [PMID: 21572407]
|
CLIP-seq Support 1 for dataset GSM545216 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / miR-124 transfection |
Location of target site | ENST00000178638.3 | 3UTR | ACAAAACCUUUAAUCUGCACCUUACAACUCG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM714644 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repA |
Location of target site | ENST00000178638.3 | 3UTR | ACAAAACCUUUAAUCUGCACCUUACAACUCGGGGACAA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM714645 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / completeT1, repB |
Location of target site | ENST00000178638.3 | 3UTR | ACAAAACCUUUAAUCUGCACCUUACAACUCGGGGAC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 21572407 / GSE28865 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
53 hsa-miR-103b Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT218386 | E2F3 | E2F transcription factor 3 | 2 | 2 | ||||||||
MIRT404221 | RPL7L1 | ribosomal protein L7 like 1 | 2 | 2 | ||||||||
MIRT441502 | SPG20 | spartin | 2 | 6 | ||||||||
MIRT444124 | ZNRF3 | zinc and ring finger 3 | 2 | 2 | ||||||||
MIRT454236 | OSBPL10 | oxysterol binding protein like 10 | 2 | 4 | ||||||||
MIRT457919 | ZNF212 | zinc finger protein 212 | 2 | 2 | ||||||||
MIRT462254 | LAMA4 | laminin subunit alpha 4 | 2 | 2 | ||||||||
MIRT463176 | ZNF281 | zinc finger protein 281 | 2 | 2 | ||||||||
MIRT472355 | TSPAN1 | tetraspanin 1 | 2 | 2 | ||||||||
MIRT474133 | LIN54 | lin-54 DREAM MuvB core complex component | 2 | 4 | ||||||||
MIRT494946 | IFFO2 | intermediate filament family orphan 2 | 2 | 2 | ||||||||
MIRT497403 | NPY4R | neuropeptide Y receptor Y4 | 2 | 2 | ||||||||
MIRT497641 | GLDN | gliomedin | 2 | 2 | ||||||||
MIRT505340 | TMEM245 | transmembrane protein 245 | 2 | 6 | ||||||||
MIRT505680 | SESTD1 | SEC14 and spectrin domain containing 1 | 2 | 6 | ||||||||
MIRT510706 | SREK1IP1 | SREK1 interacting protein 1 | 2 | 6 | ||||||||
MIRT512198 | C1orf43 | chromosome 1 open reading frame 43 | 2 | 2 | ||||||||
MIRT522089 | NUFIP2 | NUFIP2, FMR1 interacting protein 2 | 2 | 4 | ||||||||
MIRT525074 | FRK | fyn related Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT531276 | PPIL3 | peptidylprolyl isomerase like 3 | 2 | 2 | ||||||||
MIRT535119 | PLXNA2 | plexin A2 | 2 | 2 | ||||||||
MIRT540836 | GNAT1 | G protein subunit alpha transducin 1 | 2 | 4 | ||||||||
MIRT541018 | WIPI2 | WD repeat domain, phosphoinositide interacting 2 | 2 | 2 | ||||||||
MIRT545752 | CA12 | carbonic anhydrase 12 | 2 | 4 | ||||||||
MIRT546404 | SRP9 | signal recognition particle 9 | 2 | 2 | ||||||||
MIRT547991 | HCFC2 | host cell factor C2 | 2 | 4 | ||||||||
MIRT554502 | SAE1 | SUMO1 activating enzyme subunit 1 | 2 | 2 | ||||||||
MIRT558360 | DMTF1 | cyclin D binding myb like transcription factor 1 | 2 | 2 | ||||||||
MIRT558863 | CD2AP | CD2 associated protein | 2 | 2 | ||||||||
MIRT559939 | ZNF567 | zinc finger protein 567 | 2 | 2 | ||||||||
MIRT566300 | PPM1A | protein phosphatase, Mg2+/Mn2+ dependent 1A | 2 | 2 | ||||||||
MIRT567490 | FOXK1 | forkhead box K1 | 2 | 2 | ||||||||
MIRT617139 | ZNF556 | zinc finger protein 556 | 2 | 2 | ||||||||
MIRT625400 | AKR7L | aldo-keto reductase family 7 like (gene/pseudogene) | 2 | 2 | ||||||||
MIRT626491 | CEP89 | centrosomal protein 89 | 2 | 2 | ||||||||
MIRT629487 | GSN | gelsolin | 2 | 4 | ||||||||
MIRT638456 | PLXDC2 | plexin domain containing 2 | 2 | 2 | ||||||||
MIRT648498 | CMBL | carboxymethylenebutenolidase homolog | 2 | 2 | ||||||||
MIRT654845 | PPM1L | protein phosphatase, Mg2+/Mn2+ dependent 1L | 2 | 2 | ||||||||
MIRT664587 | HSD17B12 | hydroxysteroid 17-beta dehydrogenase 12 | 2 | 2 | ||||||||
MIRT664977 | TDRD1 | tudor domain containing 1 | 2 | 2 | ||||||||
MIRT665028 | ELK1 | ELK1, ETS transcription factor | 2 | 2 | ||||||||
MIRT666043 | STON2 | stonin 2 | 2 | 2 | ||||||||
MIRT668863 | CRY2 | cryptochrome circadian clock 2 | 2 | 2 | ||||||||
MIRT669297 | C17orf85 | nuclear cap binding subunit 3 | 2 | 2 | ||||||||
MIRT680975 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 | 2 | ||||||||
MIRT682267 | RS1 | retinoschisin 1 | 2 | 2 | ||||||||
MIRT685283 | KIAA1143 | KIAA1143 | 2 | 2 | ||||||||
MIRT693375 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 | 2 | ||||||||
MIRT701785 | MSL1 | male specific lethal 1 homolog | 2 | 2 | ||||||||
MIRT709373 | SPECC1 | sperm antigen with calponin homology and coiled-coil domains 1 | 2 | 2 | ||||||||
MIRT715154 | IL12B | interleukin 12B | 2 | 2 | ||||||||
MIRT734499 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 3 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|